Diabetic Macular Edema Market

Diabetic Macular Edema Market – Overview

The global diabetic macular edema market is projected to grow at a promising rate from 2021 to 2031 (forecast period). Diabetic macular edema is a leading cause of visual impairment in diabetic people. It is mainly caused by the hyper-permeability of the retinal vasculature. The causes of diabetic macular edema are multifaceted, necessitating a study of the pathogenesis and molecular pathways engaged in the disease's development.

In recent years, pharmaceutical firms have pursued combinations of many medicines to treat diabetic macular edema, targeting separate pathways or different phases of the same pathway. Some proven therapies are focused on protecting the patient's eyesight and preventing future vision loss through laser surgery and medication.

Diabetic Macular Edema Market – Competitive Landscape

Key players operating in the global diabetic macular edema market are Clearside Biomedical Inc Pfizer Inc., Allergan PLC, Ariam Pharmaceuticals, Novartis AG, Valeant Pharmaceuticals, pSivida Corporation, Regenron PLC, Bayer AG, and Alimera Sciences Inc.

Some of the institutes involved in clinical trials for the treatment of diabetic macular edema are The National Eye Institute, ShahidBeheshti University of Medical Sciences, Diabetic Retinopathy Clinical Research Network, and Johns Hopkins University.

KSI 301 (Kodiak Sciences Inc.), Faricimab (Roche), and Beovu (Novartis) late-stage drugs showed good results in diabetic macular edema in May 2021.

Diabetic Macular Edema Market – Trends and Opportunities

The growing prevalence of eye ailments such as various forms of macular edema is expected to drive the global diabetic macular edema market during the forecast period. Diabetic macular edema is becoming more common as the prevalence of diabetes rises. Diabetic macular edema is more common in type 2 diabetes patients than in type 1 diabetes patients. According to a study performed by the University Hospital Sant Joan de Reus in Spain, the worldwide prevalence of diabetic macular edema is in the range of 0.9% to 2.3% every year.

Moreover, rising research & development in treatment alternatives, a greater emphasis on preventative medical care through routine eye checkups, and rising awareness about eye health are factors projected to boost the growth of the global diabetic macular edema market. According to the Centers for Disease Control and Prevention, approximately 34.2 million people in the United States had diabetes in 2018. Many people get type 1 and type 2 diabetes at an early age, and ethnic minorities are more likely to develop type 2 diabetes later in life.

Diabetes management has become a public health concern in developed nations such as the United States. There is a dearth of focus on diabetic macular edema care and a greater emphasis on other diabetes-related complications. Anti-VEGF and corticosteroid therapy has changed the course of diabetic macular edema. However, there is still inadequate understanding among clinicians, which may affect the global market. Moreover, improvements in ophthalmic surgery procedures and investment in research and development by several pharmaceutical companies are anticipated to provide growth potential for the diabetic macular edema market expansion.

Furthermore, the intravitreal injection segment is expected to experience considerable growth as it aids cure several retinal conditions. Diabetic retinopathy and retinal vein occlusion are the most common conditions medicated with intravitreal anti-VEGF drugs due to their ease of availability and lower cost than intravitreal implants.

Diabetic Macular Edema Market – Regional Landscape

The North America diabetic macular edema market is expected to grow due to the presence of significant key players, increased penetration of episodic therapies, a rising prevalence of type 2 diabetes, and the presence of a top-tier photocoagulation laser.

The Asia Pacific diabetic macular edema market is projected to rise due to an increasing patient pool, growing expenditure in the healthcare sector, and increased government assistance. Moreover, the presence of major and domestic photocoagulation laser manufacturers is expected to promote growth in the regional market.